Replies to post #753289 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

J-To,



“One crumb of evidence” might be found among the contract references on page 28 of the recent SEC filing.

Although details are not publicly available yet, we might speculate that “deals” including research collaborations could have been inked with Oncovir, AIM ImmunoTech, and/or any of the companies that make PD-1 drugs. This is a reasonable evidence-based possibility because NWBO’s DC platforms are currently in PII combo trials with pembrolizumab and Ampligen®, and the Hiltonol combo study has concluded and was peer-reviewed.

Another “crumb” can be found around timestamp -1:03 of the ASM recording linked below:

“We have been quietly in-licensing quite a number of different pieces of technology… We also have been putting some collaborations in place …we have not announced those yet…”

https://nwbio.com/audio-of-nwbio-2023-annual-shareholders-meeting/







https://www.sec.gov/ix?doc=/Archives/edgar/data/1072379/000141057824001879/nwbo-20240930x10q.htm


https://www.nature.com/articles/s41467-024-48073-y

[XMaster2023]

The recertification of advent. Why?